OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also …
Over the last 12 months, insiders at OptiNose, Inc. have bought $0 and sold $377,781 worth of OptiNose, Inc. stock.
On average, over the past 5 years, insiders at OptiNose, Inc. have bought $227,180 and sold $754,447 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 34,000 shares for transaction amount of $104,040 was made by Clavelli Victor M (Chief Commercial Officer) on 2021‑05‑20.
2024-12-17 | Sale | Chief Executive Officer | 4,614 0.003% | $0.44 | $2,030 | -8.09% | ||
2024-12-17 | Sale | Chief Legal Officer & Corp Sec | 3,050 0.002% | $0.44 | $1,342 | -8.09% | ||
2024-09-17 | Sale | Chief Executive Officer | 4,881 0.0033% | $0.87 | $4,246 | -22.05% | ||
2024-09-17 | Sale | Chief Legal Officer & Corp Sec | 3,226 0.0022% | $0.87 | $2,807 | -22.05% | ||
2024-07-17 | Sale | Chief Executive Officer | 111,426 0.0797% | $1.14 | $127,026 | -31.82% | ||
2024-07-17 | Sale | Chief Legal Officer & Corp Sec | 49,408 0.0354% | $1.14 | $56,325 | -31.82% | ||
2024-07-17 | Sale | Chief Accounting Officer | 6,845 0.0049% | $1.14 | $7,803 | -31.82% | ||
2024-06-18 | Sale | Chief Executive Officer | 18,987 0.0124% | $1.19 | $22,595 | -33.12% | ||
2024-06-18 | Sale | Chief Legal Officer & Corp Sec | 3,267 0.0021% | $1.19 | $3,888 | -33.12% | ||
2024-06-18 | Sale | Chief Legal Officer & Corp Sec | 6,213 0.0041% | $1.19 | $7,393 | -33.12% | ||
2024-06-18 | Sale | Chief Legal Officer & Corp Sec | 2,946 0.0019% | $1.19 | $3,506 | -33.12% | ||
2024-06-18 | Sale | Chief Accounting Officer | 624 0.0004% | $1.19 | $743 | -33.12% | ||
2024-03-18 | Sale | Chief Executive Officer | 19,198 0.0166% | $1.88 | $36,092 | -49.97% | ||
2024-03-18 | Sale | Chief Legal Officer & Corp Sec | 15,059 0.013% | $1.88 | $28,311 | -49.97% | ||
2024-03-18 | Sale | Chief Accounting Officer | 2,345 0.002% | $1.88 | $4,409 | -49.97% | ||
2024-01-31 | Sale | Chief Executive Officer | 52,875 0.046% | $1.31 | $69,266 | -17.46% | ||
2023-12-18 | Sale | Chief Executive Officer | 11,114 0.01% | $1.15 | $12,781 | -6.09% | ||
2023-12-18 | Sale | Chief Legal Officer & Corp Sec | 5,005 0.0045% | $1.15 | $5,756 | -6.09% | ||
2023-09-18 | Sale | Chief Executive Officer | 11,083 0.0098% | $1.37 | $15,184 | -12.32% | ||
2023-09-18 | Sale | Chief Legal Officer & Corp Sec | 4,991 0.0044% | $1.37 | $6,838 | -12.32% |
Marino Michael F III | Chief Legal Officer & Corp Sec | 544188 0.3608% | $0.41 | 7 | 21 | <0.0001% |
Miller Peter K | Chief Executive Officer | 853384 0.5658% | $0.41 | 6 | 17 | <0.0001% |
Clavelli Victor M | Chief Commercial Officer | 199955 0.1326% | $0.41 | 1 | 7 | <0.0001% |
Goldan Keith A. | Chief Financial Officer | 141726 0.094% | $0.41 | 1 | 5 | <0.0001% |
Scodari Joseph C | director | 31230 0.0207% | $0.41 | 4 | 0 | <0.0001% |
Mvm Partners Llc | $21.25M | 10.08 | 14.61M | 0% | +$0 | 13.68 | |
Fidelity Investments | $21.27M | 10.06 | 14.57M | -0.68% | -$144,723.96 | <0.01 | |
Great Point Partners | $12.83M | 6.07 | 8.79M | -0.61% | -$78,286.66 | 2.15 | |
BlackRock | $6.25M | 2.96 | 4.28M | -2.75% | -$176,565.12 | <0.0001 | |
The Vanguard Group | $6.19M | 2.93 | 4.24M | +1.5% | +$91,842.77 | <0.0001 |